Ajax Therapeutics plans to take its type II JAK2 inhibitor into the clinic during the second half of 2024 with the aim of modifying disease in a way that first-generation type I inhibitors do not. 

Industry-wide, the combination of PD-1/PD-L1 inhibitors with TIGIT inhibitors has produced a mixed bag in terms of results.

The Japanese company will await imaging results to see if AC Immune’s candidate ACI-24.060 can help prevent or remove plaques before finalizing the deal.

Ebglyss sales, all from Germany, were €3.6m in the first quarter and while that may appear a little underwhelming at first glance, the Spanish drugmaker is impressed with the launch and its impact on dermatologists and patients.